Background-Myocardial ischemia and reperfusion are associated with increased production of endothelin (ET)-1. Methods and Results-We examined the effects of BQ-123, a selective ET A receptor antagonist, in 80 patients. All patients were randomly allocated to an intracoronary infusion of saline or BQ-123 (6 mol/L over 20 minutes). The reference group consisted of 20 patients undergoing coronary angiography. BQ-123 produced a 10% (PϽ0.005) increase in distal coronary artery diameter. The main study group consisted of 30 patients undergoing coronary angioplasty. All patients underwent a minimum of 3 balloon inflations (BIs). Surface and intracoronary electrocardiographic ST-segment shift as well as pain score were recorded at the end of each BI. BQ-123 or saline was given by intracoronary infusion between the second and the third BI in random allocation. In the saline group, intracoronary ST-elevation decreased from 1.26Ϯ0.55 mV during the first BI to 0.77Ϯ0.56 mV during the third BI (PϽ0.05) and the surface ST elevation decreased from 0.20Ϯ0.15 to 0.10Ϯ0.07 mV (PϽ0.05). In the BQ-123 group, the respective values were 1.22Ϯ0.48 mV and 1.13Ϯ0.62 mV (intracoronary) and 0.17Ϯ0.18 and 0.17Ϯ0.21 mV (surface) (both PϭNS). The decrease in pain score was significantly higher in the saline group (Fϭ5.97, Pϭ0.004). In 30 patients (collateral circulation group), the angioplasty protocol was repeated with the use of a pressure guide wire. BQ-123 produced a significant (Fϭ3.30, Pϭ0.04) decrease in coronary wedge pressure. Conclusions-Acute ET A receptor antagonism prevents the normal reduction of myocardial ischemia on repeated BIs during angioplasty. This may be explained by a "steal" effect through coronary collaterals. (Circulation.
T he endothelins (ETs) are a family of 21-amino acid peptides with potent vasoconstrictor actions. ET-1 is the predominant isopeptide generated by the vascular endothelium. ET-1 binds to at least 2 receptors in blood vessels: The ET A receptors are expressed only on vascular smooth muscle cells and cause contraction, whereas the ET B receptors are expressed on endothelium, causing vasodilation, and on vascular smooth muscle cells, causing contraction. In healthy men, the major receptor causing vasoconstriction, at least in the systemic circulation, is the ET A receptor. 1, 2 Endogenously produced ET-1 contributes to the maintenance of basal coronary artery tone in humans with and without coronary artery disease. 3, 4 Ischemia and reperfusion are associated with an increased cardiac production of ET-1. 5, 6 However, the pathophysiological role of ET-1 in these conditions remains contentious because results are conflicting and responses may be species dependent. [7] [8] [9] [10] [11] [12] The aim of the present study was to examine the effects of acute ET A receptor antagonism on myocardial ischemia in patients with stable angina pectoris during coronary angioplasty. Coronary angioplasty is a useful model for the study of the clinical, systemic, metabolic, and coronary hemodynamic responses to controlled coronary arterial occlusion. 13, 14 
Methods
The study was approved by the Hospital Ethics Committee, and all patients gave written informed consent. The study had 3 parts: In the study group, we studied the effects of the ET A antagonism on myocardial ischemia; in the reference group, we examined whether BQ-123 in the dose used in this study was sufficient to evoke coronary vasodilatation as a measure of effective ET A antagonism; in the collateral circulation group, we examined the effects of the ET A antagonism on collateral circulation.
All medications except for aspirin were discontinued 12 hours before the procedure. All patients were studied after an overnight fast and were not premedicated with sedatives. A standard Seldinger technique was used, and 5000 IU of heparin was administered intra-arterially.
Study Group
We studied patients undergoing elective coronary angioplasty for an isolated obstructive lesion in the proximal one third of a coronary artery. All lesions displayed an internal diameter reduction of 50% to 90%, based on the use of quantitative coronary arteriography. 15 Patients with stenoses of Ͼ90% were excluded to avoid "preinflation ischemia" caused by obstruction from the guide wire across the lesion, which would prolong the ischemic time of the first inflation compared with the second one. 14, 16 All patients fulfilled the following entry criteria: (1) history of chronic stable angina pectoris Ն3 months and (2) normal left ventricular ejection fraction.
Exclusion criteria were unstable angina, patients under medication with sulfonylurea or theophylline drugs (because of their effects on adenosine triphosphate sensitive potassium channels, which have a known effect on ischemic preconditioning), conduction defects or baseline ST-segment abnormalities on the ECG, history or ECG evidence of previous myocardial infarction, angiographic evidence of collateral circulation, evidence of left ventricular hypertrophy on the ECG, or history of systemic hypertension.
Protocol
The patients were randomly allocated in a single-blinded manner to 1 of 2 groups. The BQ-123 group consisted of 15 patients who received an intracoronary infusion of BQ-123. The control group consisted of 15 patients who received intracoronary normal saline (Table 1) . During the procedure and until the end of the third balloon inflation (BI), no medication except for heparin or intracoronary BQ-123 was given. If 1 or more of the following conditions occurred, the patient was excluded: (a) if nitroglycerin or any other medication was needed, (b) if intracoronary ST elevation during the first BI was Ͻ0.5 mV, or (c) if severe chest pain or arrhythmia was noted.
After the balloon was positioned across the lesion, 3 BIs of 120-seconds duration were performed (Figure 1) . A minimum period of 5 minutes was allowed for reperfusion between the first and second BIs and a 25-minute period between the second and the third BIs.
Five minutes after the second BI, the ET A receptor antagonist
was administered through the guiding catheter in the dilated artery. The substance was dissolved in 0.9% saline and was given by intracoronary infusion at a constant rate of 1 mL/min (300 nmol/min) for 20 minutes with an infusion pump. Similarly, in the control group, 0.9% saline was infused at a rate of 1 mL/min for 20 minutes.
The dose of BQ-123 administered in this study (total dose of 6 mol/L) has been shown in other studies not to cause systemic hemodynamic effects. 17, 18 In the present study, this dose was administered directly into the coronary circulation to maximize delivery of the drug to the heart. The local concentrations achieved are likely to be greater than the IC 50 at the ET A receptor but still selective for inhibition of the ET A receptor, given the Ϸ2500-foldgreater selectivity of BQ-123 for this receptor, over the ET B receptor. 19 After the third BI sequence, the experimental portion of the procedure was completed and coronary angioplasty then was concluded in accordance with standard clinical criteria.
Assessment of Myocardial Ischemia
Lead V 5 of the ECG was connected to the coronary guide wire. 20 The intracoronary ECG along with 2 other surface ECG leads chosen to reflect likely areas of ischemia during angioplasty were recorded (Mingograf, Siemens) at a paper speed of 25 mm/s throughout the study. Intracoronary and surface ECG estimations were carried out at the end of 120 seconds during the first 3 BIs. The ECGs were analyzed by a physician who had no knowledge of the study protocol. ST-segment elevation was measured 80 ms after the J-point. The severity of myocardial ischemia was expressed in terms of (1) the ST elevation from baseline on the intracoronary ECG; (2) the ST-segment elevation on the surface ECG lead with the largest ST shift (expressed in mV); and (3) pain score.
Assessment of Cardiac Pain
At the beginning of each coronary angioplasty procedure, patients were informed that they might have chest pain. At the end of the first 3 BIs, the intensity of cardiac pain was assessed by the use of a visual analog scale. 21 Patients were asked to put a mark on a 100-mm scale marked from no symptoms (0) to severe symptoms (100).
Reference Group
The reference group consisted of 20 patients studied after diagnostic coronary arteriography (Table 2) . ET A -receptor inhibition was assessed by examining the magnitude of coronary vasodilation with the use of quantitative computerized analysis with an automated edge contour detection analysis system. 15 This group had the same inclusion and exclusion criteria as the study group patients. The patients were randomly assigned to receive either BQ-123 or saline, through the diagnostic catheter, in the diseased artery. Ten patients received intracoronary BQ-123 (300 BIs. Intracoronary and surface ECGs as well as pain score in study group and coronary wedge and mean arterial pressure in collateral circulation group were taken immediately before termination of 3 BIs. Five minutes after second BI, BQ-123 or saline was infused for 20 minutes.
nmol/min, 1 mL/min, for 20 minutes); the remaining 10 patients received intracoronary saline (1 mL/min for 20 minutes). Before and after the end of BQ-123 or saline infusion, coronary arteriography was performed.
Collateral Circulation Group
We studied 30 patients undergoing elective coronary angioplasty, having the same inclusion and exclusion criteria as the study group patients. These patients were randomly allocated to 1 of 2 groups (Table 3 ). The BQ-123 group consisted of 15 patients who received intracoronary infusion of BQ-123. The control group consisted of 15 patients who received intracoronary saline. The WaveWire, a 0.014-in-diameter, high-fidelity pressure recording guide wire (Cardiometrics) with advanced piezoresistive technology, was calibrated externally and then introduced into the hemostatic valve, advanced to the distal tip of the guide catheter, and then used to verify that equal pressures were recorded by both the guiding catheter and the pressure wire. The WaveWire was subsequently advanced into the distal part of the diseased artery. During BI, this wire gives the coronary wedge pressure (P W ). After the balloon was positioned across the lesion, 3 BIs of 120-seconds duration were performed (Figure 1 ). During the procedure and until the end of the third BI, no medication was given.
Five minutes after the second BI, BQ-123 was administered by intracoronary infusion at a constant rate of 1 mL/min (300 nmol/min) for 20 minutes through the guiding catheter in the dilated artery. Similarly, in the control group, 0.9% saline was infused at a rate of 1 mL/min for 20 minutes.
Collateral Measurement
By combining P W , obtained by means of the wave wire, with simultaneously recorded aortic pressure (P a ), obtained by means of the guiding catheter, and central venous pressure (P V ) at maximum arterial vasodilation, a quantitative index of collateral flow can be calculated. 22 This index, called fractional collateral blood flow, expresses actual collateral flow (Q C ) as a ratio to normal maximum myocardial perfusion (Q N ). The collateral circulation can be estimated according to the formula 22
P V is low and can be omitted, 22 changing Formula 1 to
The lower the ratio, the higher the impairment in the collateral perfusion of the ischemic myocardium. We performed a correlation between Formula 1 and Formula 2 in 6 patients, and we found a significant correlation (rϭ0.99, PϽ0.0001, data not shown). In the present study, Formula 2 was used.
During the 3 tested BIs, before balloon deflation arterial pressure, coronary wedge pressure and right atrial pressure (in only 6 patients) were measured (Figure 1 ).
Statistical Analysis
All data were expressed as mean valueϮSD. ANOVA with repeated measures was used for statistical analysis, followed by Tukey's honestly significant difference test for post hoc comparisons. Linear regression analysis with the least-squares difference and ANOVA were used to examine possible correlations between changes in variables and coronary artery stenosis severity or artery studied. A value of PϽ0.05 was considered statistically significant.
Results
No adverse effects as a result of the study protocol were recorded.
Reference Group
After BQ-123 administration, the proximal arterial segment dilated by 4% (PϭNS) and the distal segment by 10% (PϽ0.005). After saline administration, the arterial segments did not change significantly. Heart rate and mean blood pressure did not change in either subgroup after BQ-123 or saline administration (Table 4) . 
Study Group
Forty-five consecutive patients were initially included in the study. Of these, 15 patients were excluded because of the use of nitroglycerin (5 patients), intracoronary ST elevation during the first BI Ͻ0.5 mV (7 patients), and artery dissection (3 patients). The remaining 30 patients (age 38 to 74 years) made up the study group.
Heart rate and blood pressure did not change after BQ-123 or saline administration. Heart rate, mean blood pressure, and the double product were unchanged during the 3 BIs in both groups (Table 5 ).
In the BQ-123 group, intracoronary ST-segment elevation decreased during the second BI by 25% (PϽ0.05) and increased again during the third BI, so that the value during the third BI was comparable to that during the first BI. Intracoronary ST-segment elevation in the saline group decreased by 19% during the second BI and by 39% (both PϽ0.05 versus baseline) during the third BI. The intracoronary ST elevation during the third BI was higher (PϽ0.05) in the BQ-123 group than in the saline group (Figure 2) .
Surface ST-segment shift remained unchanged in the BQ-123 group during the second and third BIs, whereas it decreased by 40% during the second BI and by 50% during the third BI (both PϽ0.05 versus baseline) in the saline group. The surface ST-segment shift was higher (PϽ0.05) in the BQ-123 group than in the control group during the third BI ( Table 2 ). There was a highly significant correlation (rϭ0.80, PϽ0.001) between the surface and intracoronary ST-segment elevation decrease (from the first to the third BI).
Pain score decreased significantly between the first and the third BIs in both groups; however, the reduction was significantly greater in the saline group (Fϭ5.97, Pϭ0.004), (Figure 3 ). Pain score decrease (from the first to the third BI) correlated significantly with the decrease in the surface ST-segment elevation (rϭ0.49, Pϭ0.03) and with the intracoronary ST-segment elevation during the same BIs (rϭ0.52, Pϭ0.005).
Collateral Circulation Group
Heart rate and mean blood pressure were unchanged during the 3 BIs in both groups ( Table 6 ). The coronary wedge pressure in the BQ-123 group decreased, and in the control group it increased (Fϭ3.30, Pϭ0.04). The coronary wedge/ mean arterial pressure in the BQ-123 group decreased, and in the control group it increased (Fϭ4.60, Pϭ0.01). 
Discussion
Our results indicate that acute ET A -receptor blockade prevents the normal reduction in myocardial ischemia on repeated BIs in patients undergoing coronary angioplasty. These observations are based on intracoronary and surface ST-segment elevation and pain score. We discuss 2 mechanisms that provide possible explanations for our findings: (1) alteration of coronary artery tone and a steal effect on coronary collaterals and (2) reversal of ischemic preconditioning.
Alteration of Artery Tone and Steal Effect on Coronary Collaterals
Collateral vessels demonstrate increased sensitivity to certain vasoconstrictors. Donckier et al 23 demonstrated in dogs that exogenously administered ET-1 increases collateral blood flow in the ischemic myocardium. The response of coronary collateral vessels to exogenously administered ET-1 may be biphasic, depending on the concentration of ET-1 24 : After an initial increase, collateral blood flow decreases at significantly elevated plasma concentrations of ET-1. Recently, we demonstrated that local ET A -receptor antagonism with BQ-123 causes coronary vasodilation, mainly at the distal coronary arterial segments, an increase in coronary blood flow, and a decrease in the coronary artery resistance. 3 Our results in the collateral circulation group indicate that acute ET A -receptor antagonism decreases coronary collateral circulation in patients with coronary artery disease during angioplasty.
Therefore, ET A receptor antagonism may increase coronary blood flow and decrease coronary artery resistance and distal coronary pressure by dilating the distal arterial segments and the resistance arteries in the nonischemic region. These effects may cause a "steal" effect on the coronary collateral circulation (Figure 4 ).
Preconditioning and Endothelin
Myocardial preconditioning is an endogenous mechanism by which a transient period of ischemia protects the myocardium from a subsequent, longer period of ischemia. Preconditioning and activation of ET-1 during ischemia may have common pathophysiological pathways, such as activation of G proteins, phospholipase A 2 , and 5Ј-mononucleotide phosphatase. 25 Wang et al 26 tested the hypothesis that ET-1 can mimic ischemic preconditioning in isolated rabbit hearts. They concluded that high concentrations of exogenously administered ET-1 can mimic ischemic preconditioning but that endogenous ET-1 seems to contribute little to this phenomenon. 26 Similar conclusions were drawn by Erikson and Velasko, 27 who demonstrated that ET A -receptor blockade did not alter infarct size in preconditioned dogs. Therefore, it seems unlikely that the prevention of the normal reduction of myocardial ischemia on repeated BIs is the result of an effect on ischemic preconditioning.
Previous Studies of the Role of Endothelin Antagonists on Myocardial Ischemia
Studies performed in rats 7 have suggested that monoclonal antibodies directed against ET-1 could reduce infarct size in experimental models of myocardial ischemia and reperfusion.
A beneficial effect of BQ-123 on experimental infarct size has also been reported in dogs. 8 A decrease in infarct size was also observed in pigs receiving bosentan, a nonpeptide ET A /ET B receptor antagonist. 9 However, these beneficial infarct-limiting effects were not confirmed by other investigators. 10 -12 Administration of BQ-123 in dogs, 10 ET A receptor antagonist FR-139317 in rabbits 11 and bosentan in rats 12 did not affect infarct size. The explanation of these apparently conflicting results is not known and may be related to several factors, including species differences, route of administration, Coronary arteries can be divided into 2 functional components: large epicardial conductance arteries and smaller resistance arterioles. After significant narrowing of coronary artery, ischemic stimulus results in autoregulation of small resistance vessels and consequently maximal vasodilation in ischemic region. ET A antagonism, in nonischemic region, dilates distal arterial segments and resistance vessels, causing decrease in coronary artery resistance, increase in blood flow, and fall in distal coronary pressure. Fall in pressure at source of collaterals may diminish collateral flow and perfusion of ischemic myocardium. This deleterious effect is termed "coronary steal."
experimental protocol, and the chemical nature (peptide versus nonpeptide) and the dosage of the given antagonist.
Dosage and Safety of BQ-123
No adverse effect was seen during or after intracoronary BQ-123 administration in either the present or our previous study. 3 The dosage used in the reference group produced coronary vasodilation similar to that in our previous study. 3 The effects of BQ-123 on coronary tone show an effect consistent with blockade of the ET A receptor. It is not known whether the adverse effect of BQ-123 on myocardial ischemia is dose-related and is a subject for future research. In our study, we used a selective ET A -receptor antagonist. Further studies with an ET B receptor as well as a nonselective antagonist will be important to fully explore the role of ET-1 in myocardial ischemia.
Conclusions
Acute ET A receptor blockade prevents the normal reduction in myocardial ischemia on repeated BIs during angioplasty, possibly secondary to a steal effect on collateral blood flow. Our findings may have important implications for the clinical use of selective ET receptor blockers.
